Annual Meeting of the NCI Cohort Consortium (Abstract Submission): Submission #2

Submission information
Submission Number: 2
Submission ID: 185937
Submission UUID: 18a08774-33ea-456c-b710-db829461417f

Created: Tue, 07/07/2026 - 17:30
Completed: Tue, 07/07/2026 - 17:45
Changed: Tue, 07/07/2026 - 17:45

Remote IP address: 10.208.28.70
Submitted by: Anonymous
Language: English

Is draft: No
Presenter Information
Yilda
G.
Macias
M.P.H.
PhD Candidate
Department of Epidemiology, University of Washington School of Public Health; Public Health Sciences Division, Fred Hutchinson Cancer Center
Additional Authors
  • First Name: Katie
    Last Name: O'Brien
    Degrees: Ph.D, MSPH
    Affiliation: Epidemiology Branch, National Institute of Environmental Health Sciences
  • First Name: Amanda
    Last Name: Phipps
    Degrees: Ph.D., M.P.H.
    Affiliation: Department of Epidemiology, University of Washington School of Public Health; Public Health Sciences Division, Fred Hutchinson Cancer Center
  • First Name: Caroline
    Last Name: Um
    Degrees: Ph.D., M.P.H., RD
    Affiliation: Population Science, American Cancer Society
  • First Name: Nathalie
    Last Name: Kliemann
    Degrees: Ph.D.
    Affiliation: Division of Genetics and Epidemiology, The Institute of Cancer Research
  • First Name: Dale
    Last Name: Sandler
    Degrees: Ph.D., M.P.H.
    Affiliation: Epidemiology Branch, National Institute of Environmental Health Sciences
  • First Name: Martin
    Last Name: Lajous
    Degrees: M.D., ScD
    Affiliation: Center for Research on Population Health, National Institute of Public Health, Mexico; Department of Global Health and Population, Harvard T.H. Chan School of Public Health
  • First Name: Montserrat
    Last Name: Garcia-Closas
    Degrees: M.D., M.P.H., DrPH
    Affiliation: Division of Genetics and Epidemiology, The Institute of Cancer Research
  • First Name: Amy
    Last Name: Berrington de Gonzalez
    Degrees: Ph.D.
    Affiliation: Division of Genetics and Epidemiology, The Institute of Cancer Research
  • First Name: Holly
    Last Name: Harris
    Degrees: ScD, M.P.H.
    Affiliation: Department of Epidemiology, University of Washington School of Public Health; Public Health Sciences Division, Fred Hutchinson Cancer Center
Abstract Information
Polyendocrine metabolic ovarian syndrome and pancreatic cancer risk: A pooled analysis across four prospective cohorts
Background: Despite sharing several risk factors, the association between pancreatic cancer and polyendocrine metabolic ovarian syndrome (PMOS), a common endocrinopathy affecting 8-13% of reproductive-aged individuals, remains understudied. Insulin resistance, reported in 35-80% of individuals with PMOS and compounded by obesity and type 2 diabetes, represents one plausible shared mechanism. Three retrospective studies reported a positive association between PMOS and pancreatic cancer, but findings were limited by small sample sizes, single-timepoint covariate assessment, and inconsistent exposure classification.

Methods: We will utilize participant data from over 400,000 women across four prospective cohorts: the Sister Study (SIS), the Cancer Prevention Study-3 (CPS-3), the Mexican Teachers Cohort (MTC), and the Generations Study (GS). Incident pancreatic cancers were identified via self-reports, registry linkage, and mortality records. To capture a broader range of PMOS presentations, we will consider four exposure definitions: self-reported PMOS, menstrual cycle irregularity (MCI), either condition, or both conditions. Pooled logistic regression with one-year intervals will be used to estimate odds ratios and 95% confidence intervals, adjusting for time-varying covariates selected a priori based on established PMOS and pancreatic cancer associations. Cohort-specific estimates will be meta-analyzed to assess heterogeneity prior to pooling.

Results: Cohort-specific analyses have been completed for SIS and CPS-3. In SIS, all four exposures showed suggestively positive associations with pancreatic cancer risk (OR range = 1.33 – 1.43). In CPS-3, PMOS and the combined exposure could not be evaluated due to low numbers of PMOS-exposed pancreatic cancer cases; associations were null to weakly positive across MCI and either condition (OR range = 1.07 – 1.12).

Discussion: To our knowledge, this will provide the first prospective evaluation of PMOS and pancreatic cancer risk. Findings may inform risk stratification efforts for individuals with PMOS, a population disproportionately burdened by metabolic comorbidities and underrepresented in epidemiologic research.